Abstract

Conventional external-beam radiation therapy is dedicated to the treatment of localized disease, whereas radioimmunotherapy represents an innovative tool for the treatment of local or diffuse tumors. Radioimmunotherapy involves the administration of radiolabeled monoclonal antibodies that are directed specifically against tumor-associated antigens or against the tumor microenvironment. Although many tumor-associated antigens have been identified as possible targets for radioimmunotherapy of patients with hematological or solid tumors, clinical success has so far been achieved mostly with radiolabeled antibodies against CD20 ((131)I-tositumomab and (90)Y-ibritumomab tiuxetan) for the treatment of lymphoma. In this Review, we provide an update on the current challenges aimed to improve the efficacy of radioimmunotherapy and discuss the main radiobiological issues associated with clinical radioimmunotherapy.

Links

Publisher Full Text

Authors

Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D

Institution

Direction de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, F-92262, France. jean-pierre.pouget@inserm.fr

Source

Nature reviews. Clinical oncology 8:12 2011 Dec pg 720-34

MeSH

Antibodies, Monoclonal
Antigens, Neoplasm
Clinical Trials as Topic
Humans
Neoplasms
Radiobiology
Radioimmunotherapy

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22064461